Body Composition in Anti-Obesity Medication Trials-Beyond Scales

JAMA Intern Med. 2024 Apr 1;184(4):341-342. doi: 10.1001/jamainternmed.2023.7733.
No abstract available

Plain language summary

This Viewpoint contends that focusing only on weight loss as the primary weight medication end point is an inaccurate measure of medication efficacy for both patients and clinicians.

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Body Composition
  • Humans
  • Weight Loss

Substances

  • Anti-Obesity Agents